A pentapeptide enabled AL3810 liposome-based glioma-targeted therapy with immune opsonic effect attenuated

AL3810, a molecular dual inhibitor of the vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR), has earned the permission of phase II clinical trial for tumor treatment by China FDA. As a reversible ATP-competitive inhibitor, AL3810 targets ATP-binding sit...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jinyang, Lu, Jiasheng, Guo, Haiyan, Zhou, Jianfen, Wang, Songli, Jiang, Kuan, Chai, Zhilan, Yao, Shengyu, Wang, Xiaoyi, Lu, Linwei, Xie, Cao, Chen, Yi, Lu, Weiyue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7838056/
https://www.ncbi.nlm.nih.gov/pubmed/33532193
http://dx.doi.org/10.1016/j.apsb.2020.07.024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7838056/
https://www.ncbi.nlm.nih.gov/pubmed/33532193
http://dx.doi.org/10.1016/j.apsb.2020.07.024

Ejemplares similares